The SSE main board is among the most prestigious and selective capital markets in the world, requiring strong revenue, sustained profitability, stellar reputation and demonstrated innovation, spokespersons said in statement.
Joe Zhou, company CEO, said this IPO is more than a financial milestone, adding that it is a validation of TSI’s purpose, people and trust in its partners.
“From the very beginning, we’ve been driven by a simple belief: that meaningful health innovation starts by understanding real consumer needs,” he said.
“Over the past three decades, we’ve built TSI into a global platform for consumer-centric, customer-focused product innovation—where science, quality and speed come together to help brands bring effective and enjoyable solutions to market. Listing on the Shanghai Stock Exchange marks a new chapter—enabling us to scale faster, innovate deeper and expand our global impact.”
The company added that the listing also strengthens TSI’s profile with global partners and institutional investors across the world, fueling future growth through R&D investment and capacity expansion.
New manufacturing
TSI acknowledged that inclusion on the SSE supports China’s emphasis on high-quality, consumption-driven areas including health, wellness and advanced manufacturing, the latter a reflection of its emphasis on global partnerships.
TSI plans on constructing new facilities in Hong Kong, Thailand, the United States and the United Kingdom to accelerate speed to market, local regulatory compliance and proximity to partners.
The company will also expand manufacturing in Australia and China, helping to boost regional supply chain resilience.
A monumental 2025
TSI Group also announced this week that it had advanced in the prestigious global XPRIZE healthspan competition for the study of its ingredients myHMB and Hobamine.
One of the most studied nutritional ingredients available, myHMB is used for muscle recovery, building muscle and to address age-related muscle loss. Hobamine, TSI Group’s form of the naturally occurring compound 2-HOBA, supports cell health by mitigating the negative impact of damaging free radicals. This helps keep the immune system in check.
“Being selected as part of the XPRIZE Healthspan initiative is a tremendous validation of the scientific promise behind HMB (myHMB) and 2-HOBA (Hobamine),” said Dr. Naji Abumrad, MD, FACS, chief scientific officer at TSI Group. “This collaboration allows us to push the boundaries of what’s possible in aging research—moving beyond lifespan to focus on real, functional health outcomes.”
TSI is collaborating with Dr. Gustavo Duque, MD, PhD, a senior scientist at the Research Institute of the McGill University Health Centre in Montreal, and his team in the Canadian Translational Geroscience Network.
The SSE and XPRIZE are now part of the TSI legacy, which spans close to three decades and over 228 global patents.
“Looking back nearly 30 years to when Joe and I started TSI, our vision was grounded in three simple principles: quality, integrity and transparency,” said Larry Kolb, TSI Group co-founder. “We learned early on that if you stay true to those values and keep the consumer at the center of every decision, everything else will follow.”